Prothena Corporation plc (LON:0Y3M)

London flag London · Delayed Price · Currency is GBP · Price in USD
9.73
-0.02 (-0.17%)
At close: Apr 25, 2025
-55.75%
Market Cap 389.14M
Revenue (ttm) 107.96M
Net Income (ttm) -97.70M
Shares Out n/a
EPS (ttm) -1.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 285
Average Volume 451
Open 9.52
Previous Close 9.75
Day's Range 9.35 - 9.79
52-Week Range 9.16 - 33.05
Beta 0.07
RSI 30.87
Earnings Date May 2, 2025

About Prothena Corporation

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline includes birtamimab, an investigational humanized antibody, which in phase 3 clinical trial to treat patients with AL amyloidosis; and Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson’s disease and other syn... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 163
Stock Exchange London Stock Exchange
Ticker Symbol 0Y3M
Full Company Profile

Financial Performance

In 2024, Prothena Corporation's revenue was $135.16 million, an increase of 47.92% compared to the previous year's $91.37 million. Losses were -$122.31 million, -16.81% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.